Objectives: Sildenafil citrate (Viagra™) is a potent selective inhibitor of phosphodiesterase type 5 proposed for the oral treatment of erectile dysfunction (ED). The aim of this study was to evaluate its efficacy and safety when used in daily practice in patients with ED of various aetiology. Patients and Methods: From September 1998 to April 1999, 380 patients chose sildenafil as treatment for their ED. One hundred and forty–five (38%) of them suffered from psychogenic ED, 125 (33%) organic and 110 (29%) of mixed aetiology. The grade of erection achieved and the occurrence of satisfactory sexual intercourse assessed the efficacy. Safety and tolerance were evaluated recording any side effect or adverse event. Results: The overall efficacy of Viagra™ was 77%, with a response of 100% among the group of hormonal patients, 88% for psychogenic, 72% for mixed, 69% for diabetes, 65% for vascular and 60% for neurological symptoms. A few and mild to moderate side effects were recorded. Conclusion: These results indicate that the use of sildenafil citrate is an effective and well–tolerated therapy for men with ED of various aetiology with an overall success rate of 77%.

Keywords:
Sildenafil, Erection, Erectile dysfunction
1.
NIH Consensus Development Panel of Impotence: Impotence. JAMA 1993;270:83–90.
2.
Padma–Nathan H, Steers WD, Wicker PA: Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: A double blind, placebo–controlled study of 329 patients. Int J Clin Pract 1998;52:375–379.
3.
Benet AE, Melman A: The epidemiology of erectile dysfunction. Urol Clin North Am 1995;22:699–709.
4.
Feldman HA, Goldstain I, Hatzichristou DG, Krane RJ, McKinlay JB: Impotence and its medical and psychosocial results of the Massachusetts Male Aging Study. J Urol 1994;151: 54–61.
5.
Goldstein I, Lue TF, Padma–Nathan H, Rosen RC, Steers WD, Wicker PA: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397–1404.
6.
Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH: Clinical safety of oral sildenafil citrate (Viagra™) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69–74.
7.
Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen RC: Sildenafil citrate in erectile dysfunction: Near normalisation in men with broad–spectrum erectile dysfunction compared with age–matched healthy control subjects. Urology 1999;53: 800–805.
8.
Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB: Treatment of erectile dysfunction with sildenafil. Urology 1999;53:19–24.
9.
Montorsi F, McDermott TED, Morgan R, et al: Efficacy and safety of fixed dose oral Sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999;53:1011– 1017.
10.
Hanash KA: Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997;157:2135–2138.
11.
Costabile RA, Spevak M: Oral trazodone is not effective therapy for erectile dysfunction: a double blind, placebo controlled trial. J Urol 1999;161:1819–1822.
12.
Morales A, Heaton JP, Johnston B, Adam M: Oral and topical treatment of erectile dysfunction: Present and future in impotence. Urol Clin North Am 1995;22:879–886.
13.
Montorsi F, Strambi LF, Guazzoni G, et al: Effects of yohimbine–trazodone on psychogenic impotence: A randomised, double–blind, placebo–controlled study. Urology 1994;44:732– 736.
14.
Kurt U, Özkardes H, Altug U, Germiyanoglu C, Gurdal M, Erol D: The efficacy of anti–serotoninergic agents in the treatment of erectile dysfunction. J Urol 1994;152:407–409.
15.
Aydin S, Odabas Ö, Ercan M, Kara H, Agargun MY: Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non organic male sexual dysfunction. Br J Urol 1996; 77:256–260.
16.
Morales A, Surridge DHC, Marshall PG, Fenemore J: Nonhormonal pharmacological treatment of organic impotence. J Urol 1982;128: 45–47.
17.
Montague DK, Barada JH, Belker AM, et al: Clinical guidelines panel on erectile dysfunction: Summary report on the treatment of organic erectile dysfunction. J Urol 1996;156: 2007–2011.
18.
Jarow JP, Burnett AL, Geringer AM: Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162:722–725.
19.
Desvaux P, Mimoun S: Prostaglandin E1 in the treatment of erectile insufficiency. Comparison of efficacy and tolerance based on different etiologies (in French). J Urol (Paris) 1994; 100:17–22.
20.
Linet OI, Ogrinc FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334:873–877.
21.
Porst H, Buvat J, Meuleman E, Michal V, Wagner G: Intracavernous Alprostadil Alfadex – An effective and well tolerated treatment for erectile dysfunction. Results of a long–term European study. Int J Impot Res 1998;10: 225–231.
22.
Lehman K, Casella R, Blöchlinger A, Gasser TC: Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil). Urology 1999;53:397–400.
23.
Ghanem H, Sherif T, Adbel–Gawad T, Asaad T: Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction. Int J Impot Res 1998;10:211–214.
24.
Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A: Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998;52:963–966.
25.
Costabile RA, Spevak M, Fishman IJ, et al: Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998;160:1325– 1328.
26.
Porst H: Transurethral alprostadil with MUSE™ (medicated urethral system for erection) vs. intracavernous alprostadil – A comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997;9:187–192.
27.
Shokeir AA, Alserafi MA, Mutabagani H: Intracavernosal versus intraurethral Alprostadil: a prospective randomized study. BJU Int 1999; 83:812–815.
28.
Rendell MS, Rajfer J, Wicker PA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999;281:421– 426.
29.
Metro MJ, Broderick GA: Diabetes and vascular impotence: Does insulin dependence increase the relative severity? Int J Implot Res 1999;11:87–89.
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.